American Shared Hospital Services Announces First Quarter 2012 Results Earnings Conference Call
American Shared Hospital Services (NYSE AMEX:AMS), a leading
provider of turnkey technology solutions for advanced radiosurgical and
radiation therapy solutions, will hold its quarterly conference call to
American Shared Hospital Services (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy solutions, will hold its quarterly conference call to discuss first quarter of 2012 results on Monday, May 14, 2012 at 1pm Eastern Time / 10am Pacific Time. First quarter results of 2012 will be released the morning of Monday, May 14, 2012. Date/TimeMonday, May 14, 2012 at 1pm ET / 10am PT Teleconference and Webcast Information To participate, please call (800) 588-4973 at least 5 minutes prior to the start of the call. A live on-demand webcast of the call will be provided by Thomson Reuters and posted at www.ashs.com and www.earnings.com. The webcast is also being distributed over Thomson Reuters’ Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson Reuters’ individual investor center at www.earnings.com or by visiting any of the investor sites in Thomson Reuters’ Individual Investor Network. Institutional investors can access the call via Thomson Reuters’ password-protected event management site, StreetEvents ( www.streetevents.com). About AMS (www.ashs.com) American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st Century® concept. Through its preferred stock investment in Mevion Medical Systems, Inc., AMS plans to complement these services with the MEVION S250 proton beam radiation therapy (PBRT) system, which has not yet been approved by the FDA.